Thursday, November 12, 2026

EUR/CHF Slides By 1% In The Last 10 Sessions

ViaNews Editorial Team

September 8, 2024

EUR/CHF Slides By 1% In The Last 10 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 1.05% for the last 10 sessions. At 17:06 EST on Sunday, 8 September, EUR/CHF (EURCHF) is $0.94.

EUR/CHF's yearly highs and lows, it's 3.566% up from its 52-week low and 5.821% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was 0.07%, 0.02%, and 0.29%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.14% (last week), 0.32% (last month), and 0.29% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be overbought (>=80).

News about

  • According to FXStreet on Friday, 6 September, "In terms of support, the USD/JPY pair is falling toward the seven-month low of 141.69, recorded on August 5. ", "On the upside, the USD/JPY pair might first encounter a barrier at the nine-day EMA around 144.60, followed by the 21-day EMA at 146.02. "
  • Usd/jpy finds support near 142.00, recovers few pips from over one-month low ahead of NFP. According to FXStreet on Friday, 6 September, "The USD/JPY pair remains under some selling pressure for the fourth straight day and drops to over a one-month low, around the 142.00 round-figure mark on Friday. ", "Any meaningful recovery for the USD/JPY pair, however, seems elusive in the wake of divergent Fed-Bank of Japan (BoJ) policy outlook. "
  • Usd/jpy: A death cross is upon us – OCBC. According to FXStreet on Friday, 6 September, "Fed-BoJ policy shifts and growing pace of normalisation can bring about faster narrowing of UST-JGB yield differentials and this should continue to underpin the broader direction of travel for USD/JPY to the downside."
  • Usd/jpy holds losses after weak nfps from the US. According to FXStreet on Friday, 6 September, "The USD/JPY tallies 0.30% losses on Friday as the USD extends its broad weakness after soft Nonfarm Payrolls figures from the US.", "The USD/JPY outlook is negative as the Relative Strength Index (RSI) hovers near the oversold level of 30, signaling potential downward momentum which could eventually lead to a correction though. "
  • Usd/jpy price forecast: downtrend resumes boosted by falling US yields. According to FXStreet on Friday, 6 September, "The USD/JPY extended its losses late on Friday's North American session, bolstered by the losses of the yield of the US 10-year T-note. ", "The USD/JPY downtrend continued after the latest US Nonfarm Payrolls report sparked volatility in the pair, which seesawed within a 230-pip range on the day, but as the dust settled, sellers remained in charge."

More news about EUR/CHF (EURCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com